Upgrade to SI Premium - Free Trial

UBS Upgrades Cytokinetics (CYTK) to Buy

June 29, 2026 4:21 AM
(Updated - June 29, 2026 5:49 AM EDT)

UBS analyst Ashwani Verma upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Hot Upgrades Upgrades